Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Heron Therapeutics (HRTX) Receivables - Net (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Receivables - Net for 11 consecutive years, with $89.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 13.57% year-over-year to $89.6 million, compared with a TTM value of $89.6 million through Dec 2025, up 13.57%, and an annual FY2025 reading of $89.6 million, up 13.57% over the prior year.
  • Receivables - Net was $89.6 million for Q4 2025 at Heron Therapeutics, up from $81.0 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $89.6 million in Q4 2025 and bottomed at $35.5 million in Q4 2021.
  • Average Receivables - Net over 5 years is $60.1 million, with a median of $62.0 million recorded in 2023.
  • The sharpest move saw Receivables - Net dropped 15.18% in 2021, then surged 90.29% in 2023.
  • Year by year, Receivables - Net stood at $35.5 million in 2021, then surged by 46.62% to $52.0 million in 2022, then increased by 15.54% to $60.1 million in 2023, then surged by 31.17% to $78.9 million in 2024, then rose by 13.57% to $89.6 million in 2025.
  • Business Quant data shows Receivables - Net for HRTX at $89.6 million in Q4 2025, $81.0 million in Q3 2025, and $79.9 million in Q2 2025.